Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model

BackgroundPhotoimmunotherapy (PIT) uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, to induce tumor necrosis after irradiation with NIR light to kill cancer cells, such as those that remain after surgery. The purpose of the present study was to sterilize the surgical bed after pancreatic cancer resection with PIT in carcinoembryonic antigen (CEA)-expressing, patient-derived, orthotopic xenograft (PDOX) nude mouse models.MethodsAfter confirmation of tumor engraftment, mice were randomized to two groups: bright light surgery (BLS)-only and BLS + PIT. Each treatment arm consisted of seven tumor-bearing mice. BLS was performed under standard bright-field with an MVX10 long-working distance, high-magnification microscope on all mice. For BLS + PIT, anti-CEA antibody conjugated with IR700 (anti-CEA-IR700) (50 µg) was injected intravenously in all mice 24 h before surgery. After the surgery, the resection bed was then irradiated with a red-light-emitting diode at 690 ± 5 nm with a power density of 150 mW/cm2.ResultsAnti-CEA-IR700 labelled and illuminated the pancreatic cancer PDOX. Minimal residual cancer of the PDOX was detected by fluorescence after BLS. The local recurrence rate was 85.7 % for BLS-only and 28.6 % for BLS + PIT-treated mice (p = 0.05). The average recurrent tumor weight was 1149.0 ± 794.6 mg for BLS-only and 210.8 ± 336.9 mg for BLS + PIT-treated mice (p = 0.015).ConclusionAnti-CEA-IR700 was able to label and illuminate a pancreatic cancer PDOX nude mouse model sufficiently for PIT. PIT reduced recurrence by eliminating remaining residual cancer cells after BLS.

[1]  R. Hoffman,et al.  Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Yamauchi,et al.  Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. , 2006, Cancer research.

[3]  E. Klein,et al.  MHC class‐I‐restricted auto‐tumor‐specific CD4+CD8 −T‐cell clones established from autologous mixed lymphocyte‐tumor‐cell culture (MLTC) , 1992, International journal of cancer.

[4]  S. Yamada,et al.  Prognostic Factors for Survival After Extended Pancreatectomy for Pancreatic Head Cancer: Influence of Resection Margin Status on Survival , 2009, Pancreas.

[5]  H. Colt,et al.  Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice. , 1993, Anticancer research.

[6]  Hisataka Kobayashi,et al.  Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. , 2012, Bioconjugate chemistry.

[7]  Can Xu,et al.  CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. , 2012, Cancer letters.

[8]  R. Hoffman,et al.  Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. , 1993, Anticancer research.

[9]  R. Hoffman,et al.  A new patient‐like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice , 1992, International journal of cancer.

[10]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[11]  R. Hoffman,et al.  A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. , 1993, Anticancer research.

[12]  Yukihiko Hiroshima,et al.  Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer , 2015, PloS one.

[13]  H. Shimada,et al.  Host organ specifically determines cancer progression. , 1995, Cancer research.

[14]  F. Guadagni,et al.  A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Tsuneyoshi,et al.  Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19‐9 , 1991, Journal of surgical oncology.

[16]  I. Endo,et al.  Establishment of a Patient-Derived Orthotopic Xenograft (PDOX) Model of HER-2-Positive Cervical Cancer Expressing the Clinical Metastatic Pattern , 2015, PloS one.

[17]  Robert M. Hoffman,et al.  Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic , 2004, Investigational New Drugs.